BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33992087)

  • 1. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
    Mills MN; Naz A; Thawani C; Walker C; Figura NB; Kushchayev S; Oliver DE; Etame AB; Yu HM; Robinson TJ; Liu JKC; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
    BMC Cancer; 2021 May; 21(1):552. PubMed ID: 33992087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
    Mills MN; Walker C; Thawani C; Naz A; Figura NB; Kushchayev S; Etame A; Yu HM; Robinson TJ; Liu J; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Ahmed KA
    BMC Cancer; 2021 Mar; 21(1):223. PubMed ID: 33663447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-fraction radiosurgery versus fractionated stereotactic radiotherapy in patients with brain metastases: a comparative study.
    Loo M; Pin Y; Thierry A; Clavier JB
    Clin Exp Metastasis; 2020 Jun; 37(3):425-434. PubMed ID: 32185576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases.
    Mills MN; Thawani C; Figura NB; Oliver DE; Soyano AE; Etame A; Robinson TJ; Liu JK; Vogelbaum MA; Forsyth PA; Czerniecki BJ; Soliman HH; Han HS; Yu HM; Ahmed KA
    J Neurooncol; 2021 May; 152(3):591-601. PubMed ID: 33742358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
    Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis.
    Minniti G; Clarke E; Lanzetta G; Osti MF; Trasimeni G; Bozzao A; Romano A; Enrici RM
    Radiat Oncol; 2011 May; 6():48. PubMed ID: 21575163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors.
    Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW
    J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
    Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
    J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery.
    McKay WH; McTyre ER; Okoukoni C; Alphonse-Sullivan NK; Ruiz J; Munley MT; Qasem S; Lo HW; Xing F; Laxton AW; Tatter SB; Watabe K; Chan MD
    J Neurosurg; 2017 Jul; 127(1):148-156. PubMed ID: 27494815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.
    Figura NB; Potluri TK; Mohammadi H; Oliver DE; Arrington JA; Robinson TJ; Etame AB; Tran ND; Liu JK; Soliman H; Forsyth PA; Sahebjam S; Yu HM; Han HS; Ahmed KA
    J Neurooncol; 2019 Sep; 144(3):583-589. PubMed ID: 31399935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.
    Milano MT; Grimm J; Niemierko A; Soltys SG; Moiseenko V; Redmond KJ; Yorke E; Sahgal A; Xue J; Mahadevan A; Muacevic A; Marks LB; Kleinberg LR
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):68-86. PubMed ID: 32921513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
    Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
    World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of HER2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery.
    Tam M; Narayana A; Raza S; Kunnakkat S; Golfinos JG; Parker EC; Novik Y
    Med Oncol; 2014 Feb; 31(2):832. PubMed ID: 24390418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases.
    Hirata M; Yasui K; Oota N; Ogawa H; Onoe T; Maki S; Ito Y; Hayashi K; Asakura H; Murayama S; Mitsuya K; Deguchi S; Nakamura K; Hayashi N; Nishimura T; Harada H
    Radiat Oncol; 2022 Dec; 17(1):213. PubMed ID: 36578021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adjuvant fractionated stereotactic radiotherapy dose on local control of brain metastases.
    Musunuru HB; Witt JS; Yadav P; Francis DM; Kuczmarska-Haas A; Labby ZE; Bassetti MF; Howard SP; Baschnagel AM
    J Neurooncol; 2019 Nov; 145(2):385-390. PubMed ID: 31606876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases.
    Khatri VM; Mills MN; Oliver DE; Yu HM; Vogelbaum MA; Forsyth PA; Soliman HH; Han HS; Ahmed KA
    J Neurooncol; 2023 Aug; 164(1):191-197. PubMed ID: 37490232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience.
    Gao C; Wang F; Suki D; Strom E; Li J; Sawaya R; Hsu L; Raghavendra A; Tripathy D; Ibrahim NK
    Int J Cancer; 2021 Feb; 148(4):961-970. PubMed ID: 32748402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiosurgery for intraventricular brain metastases.
    Farnia B; Voong KR; Brown PD; Allen PK; Guha-Thakurta N; Prabhu SS; Rao G; Wang Q; Zhao Z; Mahajan A
    J Neurosurg; 2014 Dec; 121 Suppl():26-34. PubMed ID: 25434934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.